InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (17 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
17
T+90 hit rate
0%
T+90 mean return
-62.9%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Wilson Mark Andrew, Directeur Juridique. Insider active across 2 companies, notably NEKTAR THERAPEUTICS. Cumulatively, 21 filings have been recorded. Breakdown: 0 buy · 17 sells. Total volume traded: €253k. Activity tracked since 17 May 2021. The latest transaction was disclosed on 19 August 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations21 total
676 shares@ US$26.59Common StockSEC:0000950170-25-110774:0
9,996 shares@ US$0.671.8% of flowCommon StockSEC:0000950170-25-075977:0
11,040 shares@ US$1.013.3% of flowCommon StockSEC:0000950170-25-025040:0
33,402 shares@ US$0.908.9% of flowCommon StockSEC:0000950170-24-140591:0
165,938 shares0Common StockSEC:0000950170-24-137544:0
6,407 shares@ US$1.011.9% of flowCommon StockSEC:0000950170-24-129462:0
5,651 shares@ US$1.282.0% of flowCommon StockSEC:0000950170-24-099353:0
6,260 shares@ US$1.753.1% of flowCommon StockSEC:0000950170-24-062644:0
7,606 shares@ US$0.681.5% of flowCommon StockSEC:0000950170-24-019044:0
7,179 shares@ US$0.491.0% of flowCommon StockSEC:0001209191-23-056183:0
7,221 shares@ US$0.781.6% of flowCommon StockSEC:0001209191-23-046461:0
7,543 shares@ US$0.721.5% of flowCommon StockSEC:0001209191-23-030447:0
8,275 shares@ US$3.007.2% of flowCommon StockSEC:0001209191-23-010954:0
8,690 shares@ US$3.579.2% of flowCommon StockSEC:0001209191-22-057967:0
165,938 shares0Common StockSEC:0001209191-22-046488:0
3,136 shares@ US$3.950.0005% mcap6.4% of flowCommon StockSEC:0001209191-22-029904:0
3,661 shares@ US$10.950.0015% mcap19.1% of flowCommon StockSEC:0001209191-22-011441:0
37,800 shares0Common StockSEC:0001209191-21-070695:0
20,100 shares0Common StockSEC:0001209191-21-065225:0
1,910 shares@ US$13.830.0009% mcap12.1% of flowCommon StockSEC:0001209191-21-052393:0
1,917 shares@ US$18.300.0012% mcap15.6% of flowCommon StockSEC:0001209191-21-034190:0
21 of 21 declarations
About Wilson Mark Andrew
Mark Andrew Wilson is the General Counsel and SVP at Nektar Therapeutics. He is responsible for managing the company's legal affairs and regulatory compliance. With a strong background in corporate law, Mark plays a key role in protecting the company's interests and managing legal risks. His expertise is essential for ensuring compliance with laws and regulations.
